DocWire News Editors

DocwireNews

Here are the top stories covered by DocWire News this week in the Hematology &amp; Oncology section. This week, a report indicated that the number of U.S. cancer survivors is growing, the U.S. Food and Drug Administration approved new treatment for head and neck cancer and lymphoma, and more.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/number-of-cancer-survivors-projected-to-top-22-million-by-2030/">The total number of&nbsp;cancer survivors&nbsp;</a>in the United States is projected to expand from 16.9 million Americans in 2019 to more than 22.1 million by 2030, according to a study published in&nbsp;CA: A Cancer Journal for Clinicians. This&nbsp;growth in survivorship continues to climb despite the cancer incidence rate remaining stable in women and declining in men. This increase in survivorship is related to the growing aging population, as well as advances in early detection and treatment, according to the researchers.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-keytruda-firstline-head-neck-cancer/">The FDA approved Keytruda&reg;</a> (pembrolizumab) for firstline treatment of patients with metastatic or unresectable recurrent&nbsp;head and neck squamous cell carcinoma. In the KEYNOTE-048 study, patients receiving pembrolizumab plus chemotherapy had statistically significant improvement in overall survival compared with those receiving cetuximab plus chemotherapy.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-approves-polivy-chemoimmunotherapy-dlbcl/">The FDA granted accelerated approval to Polivy&trade;</a> (polatuzumab vedotin-piiq), a CD79b-directed antibody-drug conjugate, in combination with bendamustine and rituximab for adult patients with relapsed/refractory&nbsp;diffuse large B-cell lymphoma, not otherwise specified, who received at least two prior therapies. In the GO29365 trial, the complete response rate was 40% among patients receiving polatuzumab vedotin-piiq plus bendamustine and rituximab versus 18% in those receiving bendamustine plus rituximab alone.For patients with end-stage cancer, <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/care-planning-facilitates-quality-of-life/">advanced care planning documentation can prevent avoidable hospital admissions</a> at the end of life , according to researchers from Ohio State University who published their&nbsp;findings&nbsp;in the&nbsp;American Journal of Hospice and Palliative Medicine. According to the results of the study, patients with an order of a verified do-not-resuscitate (DNR) prior to the last 30 days of life had diminished odds of unnecessary admission compared to those without a DNR.

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Latest News

Hem/Onc Highlights: Number of Cancer Survivors to Top 22 Million by 2030, New FDA Approvals, and more

Oncology

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, a report indicated that the number of U.S. cancer survivors 

Hem/Onc Highlights: Number of Cancer Survivors to Top 22 Million by 2030, New FDA Approvals, and

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe